key: cord-0894303-w6vrido8
authors: Díez, José María; Romero, Carolina; Gajardo, Rodrigo
title: Effective presence of antibodies against common human coronavirus in IgG immunoglobulin medicinal products. Antibodies to common coronaviruses in IgG medicinal products
date: 2021-12-17
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.12.329
sha: 58898c01a4b5bbca1f2ce96ff15712d7027fe319
doc_id: 894303
cord_uid: w6vrido8

Background: In these studies, immunoglobulin (IgG) products (IV, IM, SC) prepared from geographically diverse plasma pools were tested for activity against common human coronaviruses (HCoV). Products from plasma obtained from Germany, Czech Republic, Slovak Republic, USA, and Spain were tested for antibodies to common HCoV: 229E, OC43, NL63, and HKU1. Since these products are manufactured from pooled plasma from thousands of donors, the antibodies therein are representative of HCoV exposure in the population at large. Methods: IgG products were tested for antibodies to four common HCoV by ELISA. Neutralization assays were conducted using HCoV-229E cultured onto MRC5 cells. Results: The ELISA assays showed that when expressed as specific activity (anti-HCoV activity/mg IgG) similar activity against the four common HCoV was seen across the IgG products regardless of concentration or geographic origin. Highest anti-HCoV activity was seen against HCoV-229E, followed by HCoV-OC43, and then HCoV-NL63 and HCoV-HKU1. The neutralization assays showed similar potency for two preparations of IgG prepared by different processes. Conclusions: This is the first demonstration of antibodies to common HCoV in IgG products. These results may explain the cross-reactivity seen with pre-pandemic IgG products and SARS-CoV-2 and contribute to the variability in disease course in different patients.

Until the appearance of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) pandemic, relatively little attention has been paid to the classical endemic human coronaviruses (Li et al., 2021) . Common human coronaviruses (HCoVs) are globally distributed (Anthony et al., 2017) . They are responsible for a large proportion of respiratory infections that are mild in most cases for immunocompetent individuals. To date, four main subtypes of common HCoVs have been identified: HCoV-229E (Hamre and Procknow, 1966) , HCoV-NL63 (Van Der Hoek et al., 2004) , HCoV-OC43 (McIntosh et al., 1967) and HCoV-HKU1 (Woo et al., 2005) . HCoV-229E and HCoV-OC43 were discovered in 1966 and 1967, respectively, whereas HCoV-NL63 and  HCoV-HKU1 were identified in 2005. None of these viruses have been found to be maintained within an animal reservoir (Su et al., 2016) Due to the ubiquity of these viruses, antibodies against common HCoVs are expected to be widely distributed in the population. Nevertheless, to our knowledge few systematic epidemiological surveys at the population level have been performed and not globally (Killerby et al., 2018) . There are studies looking at the proportion of infections in some specific groups of patients (Gaunt et al., 2010; Ruetalo et al., 2021) .

Since a large proportion of the infections are in the childhood, whether the antibodies persist in the adult population and at what magnitude are not well known. Moreover, distinct antibody reservoirs against endemic human coronaviruses in children and adults have been described (Khan et al., 2021) . Because purified medicinal immunoglobulin solutions are polyvalent and are prepared from donor plasma pools from thousands of individuals, they cover a broad spectrum of immunity in the general population and would be expected to include anti-coronavirus antibodies reflecting both the proportion of infections caused by each subtype and the specific antibody titer in the donor (general) population.

It is important to note that coronaviruses in the same subgroup, particularly betacoronaviruses such as HCoV-OC43, HCoV-HKU1, SARS-CoV, SARS-CoV-2, and MERS-CoV, show some interactivity in antigenic responses. Cross reactivity between SARS-CoV and MERS-CoV with other human betacoronaviruses has become apparent (Che et al., 2005; Patrick et al., 2006; Chan et al. 2013) . The fact that the new betacoronavirus SARS-CoV-2 is directly related to SARS-CoV (they share more than 90% sequence homology) (Guo et al., 2020) suggests that antigenic interactivity between them is possible, at least for some proteins. In addition, recently, reactions to SARS-CoV-2 in pre-pandemic immunoglobulin solutions have been observed. (Díez et al., 2020a) Furthermore, these solutions have some neutralizing capacity. (Díez et al., 2020b) Neutralization activity is primarily mediated through the spike (S) glycoprotein, the primary protein involved in the binding of coronaviruses to host cells. (Qian et al., 2015; Jiang et al., 2020) In this study, immunoglobulin (IgG) solutions for intravenous, intramuscular, and subcutaneous administration were analyzed for the presence of antibodies to common HCoV. This project was designed to detect, for the first time, common HCoV antibodies in immunoglobulin IgG solutions. The immunoglobulins solutions were obtained from plasma from different origins (Germany, Czech Republic, Slovak Republic, USA, and Spain) allowing an indirect comparison of the epidemiology of these viruses in these geographical areas.

The immunoglobulin solutions used in this study were all produced by Grifols (Barcelona, Spain, and Research Triangle Park, NC, USA). They included intravenous solutions (Flebogamma ® DIF 5% and 10% and Gamunex ® -C 10%), intramuscular solutions (Gamastan ® 15-18% and Igamplia ® 16%) and a subcutaneous solution (Xembify ® 20%). These products were obtained from plasma pools from different origin (Germany, Czech Republic, Slovak Republic, USA, and Spain). The collection dates for the plasma units are shown in Table 1 .

Antibodies (IgG) to the common coronaviruses were detected using ELISA kits (Alpha Diagnostic Intl., San Antonio, TX, USA). For the α-coronaviruses the following kits were used: RV-406100 Recombivirus Human anti-HCoV 229E S1 IgG ELISA Kit and RV-406115 Recombivirus Human anti-HCoV NL63 S1 IgG ELISA Kit. For the βcoronaviruses, these kits were used: RV-406130 Recombivirus Human anti-HCoV OC43 Spike IgG ELISA Kit and RV-406145 Recombivirus Human anti-HCoV HKU1 S1

IgG ELISA Kit. The ELISAs were performed according to the manufacturer's instructions. Data were analyzed as suggested by the kit manufacturer. The antibody potency was calculated multiplying positivity ratio for the inverse of the most diluted positive sample relative to the low calibrator from the kit. Samples were tested in duplicate.

Neutralization assays was performed using HCoV-229E coronavirus. Briefly, different immunoglobulin solutions (Flebogamma ® DIF and Gamunex®-C) were incubated with 100 infectious units of the 229E virus for 1 . 5 hours at 37 ± 2 ºC. MRC5 cells ( 

The IgG titers (anti-coronavirus activity/mL) for the immunoglobulin products are shown in Figure 1 . When expressed in this manner, the lower concentration of immunoglobulins (5%) showed less activity than the higher concentrations (10-20%).

For products of similar concentration, IgG activity was similar regardless of the geographic origin of the plasma pool. Overall, the highest activity was seen against the HCoV-229E and HCoV-OC43 strains.

The similarity becomes clearer when the data were expressed as specific activity (anticoronavirus activity/mg IgG: Figure 2 ). These data show that anti-coronavirus activity was consistent across the products regardless of the total IgG concentration and the origin of the plasma pool. Activity was highest against the HCoV-229E followed by HCoV-OC43. Similar lower level activity was seen against HCoV-NL63 and HCoV-HKU1.

When the data from all the products was combined, the mean specific activity against Functional characterization of these antibodies was performed by infectivity neutralization assays using HCoV-229E .When neutralization assays were performed using the HCoV-229E virus in MRC5 cells, the concentration-effect curves for two types of intravenous immunoglobulin (IVIG) 10 % produced by different manufacturing processes (Flebogamma ® -DIF 10 %, origin: USA and Gamunex ® -C 10%, origin: USA)

were nearly superimposable. This shows that the neutralization activity of the antibodies present in these products is essentially the same regardless the manufacturing process. This demonstrates that the IgG medicinal products contain functional antibodies against common HCoVs.

For the first time, the presence of antibodies to common coronaviruses was measured in therapeutic immunoglobulin solutions (IV, IM, and SC). Anti-HCoV IgG levels were similar across products for each virus regardless of the product concentration or the geographic origin of the plasma. However, there are differences in antibody levels between viruses with higher levels of IgG HCoV-229E, with lower levels for HCoV-OC43, and similar still lower levels for HCoV-HKU1 and HCoV-NL63.

Studies on the incidence of HCoV infections treated by a healthcare provider have shown that the most common strain and prevalence depend on the geographic region and the time of year. Gaunt et al. (2010) found that the most prevalent strain of common HCoV in Edinburgh, Scotland varied from year to year and that respiratory infections due to common HCoVs showed marked seasonality. However, over the three-year data collection period, HCoV-OC43 and HCoV-NL63 were the most frequently detected common HCoVs (Gaunt et al., 2010) . Similar seasonality and variation in the predominant viral strain from year to year was also found in a study conducted in the United States (Killerby et al., 2018) .

A study in France found that HCoV-229E and HCoV-HKU1 were the most common HCoVs causing respiratory infections (Lepiller et al., 2013) . In Japan, HCoV infections were most commonly caused by HCoV-NL63 and HCoV-HKU1 with peak prevalence in the winter months and annual variation in the relative prevalence of the different common HCoV strains (Matoba et al., 2015) . One pediatric study in China found that HCoV-229E and HCoV-OC43 had the highest prevalence of the common strains for causing respiratory infections (Lin et al., 2020) while another study found HCoV-NL63 to be the most prevalent . Co-infection with other respiratory viruses was also a common finding (Gaunt et al., 2010; Lepiller et al., 2013; Lin et al., 2020) .

A global, systematic review and meta-analysis of data from 1995-2020 in pediatric and adult patients showed that OC43 was the most prevalent common HCoV (estimated prevalence 2 . 40%) followed by NL63 (1 . 60%), HKU1 (1 . 04%), and 229E (0 . 97%). These data were collected almost exclusively in developed countries (97%) (Li et al., 2021) .

Given the above studies showing differences in the prevalence of common HCoV strains in different parts of the world, it is somewhat surprising that all the IG samples in this study showed a similar pattern of anti-HCoV activity. This could be explained by the seasonal variability of the prevalence of the common HCoVs, i.e., the predominance of one strain in a given winter season followed by the predominance of a different strain in the following winter season, and that the plasma pool likely reflects HCoV exposure over time in the donors. In addition, three of the epidemiological studies previously cited were conducted in Asia (Matoba et al., 2015; Lin et al., 2020; Zhang et al., 2021) while the IG products tested in this study were from Eastern Europe, Spain, and the USA. The predominance of different HCoV strains varies in different geographical areas over time.

It is also unexpected that the antibody profile in the IG products (highest levels 229E and OC43) does not match the HCoV prevalence in the longitudinal meta-analysis (OC43 most prevalent and 229E least prevalent; Li et al, 2021) . This may reflect that the geographic source of the plasma used to produce these products is reflective of these specific regions and not representative of worldwide prevalence. Another factor that could contribute to the apparent disparity may be that the published studies represent clinical samples from patients that sought medical attention while the IG products represent a population that included individuals who had milder infections and did not seek medical attention. In other words, the epidemiology reflects patients with more symptomatic infections while the IG products include individuals that had asymptomatic or mild infections as well as symptomatic infections.

In addition, these studies demonstrated that these antibodies had neutralizing activity against HCoV-229E virus in MRC5 cells. Neutralization activity is one important factor to the use of plasma-derived products employed in the treatment and/or prevention of viral diseases. The neutralizing capacity in this study was demonstrated with two different products with different manufacturing methods. This finding suggests the ubiquity of anti-HCoV binding activity is accompanied by neutralization activity. HCoV-229E virus was employed to demonstrate neutralization activity of the antibodies detected by ELISA. Direct extrapolation cannot be made to the other common HCoVs, but it is logically expected the antibodies would have neutralization activity against them as well.

It is also important to note that coronaviruses in the same subgroup, particularly betacoronaviruses such as HCoV-OC43, HCoV-HKU1, SARS-CoV, SARS-CoV-2, and MERS-CoV, show some interactivity in antigenicity. Cross-reactivity between SARS-CoV and MERS-CoV and other human betacoronaviruses has been reported (Che et al., 2005; Patrick et al., 2006; Chan et al., 2013) . The fact that the recently identified betacoronavirus, SARS-CoV-2, is closely related to SARS-CoV (> 90% sequence homology) (Guo et al., 2020) suggests that antigenic interactivity between them is possible, at least for some proteins.

In addition, reactivity to SARS-CoV-2 in pre-pandemic immunoglobulin solutions has recently been observed (Diez et al., 2020a) . As demonstrated in this study, these solutions also have the capacity to neutralize common HCoVs such as HCoV-229E.

Furthermore, these solutions have demonstrated some neutralizing capacity towards SARS-CoV-2 (Díez et al., 2020b) . The worldwide presence of these common HCoVs may affect the current SARS-CoV-2 pandemic. Pre-existing immunity to common HCoVs may have a role in both humoral and cellular responses to SARS-CoV-2 (Díez et al., 2020b; Anderson et al., 2021; Meyerholz and Perlman 2021) and it could explain, in part, the differences in illness behavior among patients.

This observed reactivity between pre-pandemic IVIG and SARS-CoV-2 occurs despite the low protein sequence homology between the SARS-CoV-2 spike protein and common human coronaviruses (OC43 and HKU1: 30% identity; 41% similarity and 29% identity and 40% similarity, respectively). However, despite low overall homology, higher homology was observed in the C-terminal regions of the spike proteins. This region is instrumental in the insertion of the fusion protein into the cell membrane of the host cell. (Hicks et al., 2021) . The C-terminus homology could underly potential crossreactivity of antibodies to the common coronaviruses with SARS-CoV-2.

As shown in Table 1 , the majority of the pooled plasma used in the manufacture of the products tested in this study was collected prior to the COVID-19 pandemic. Two products contained plasma collected in the early stages of the pandemic (until May 2020). A study examining the presence of anti-SARS-CoV-2 antibodies in IG products demonstrated that these antibodies were not detected until late 2020 (products produced in September and October) (Romero et al., 2021) . This suggests that the observed activity against the common human coronaviruses was not due to crossreactivity from anti-SARS-CoV-2 antibodies.

In conclusion, these studies demonstrated for the first time the presence of antibodies to common HCoVs in parenteral IG products. The level of anti-HCoV activity for each virus was similar regardless of the geographic origin of the plasma pool. Neutralization activity was demonstrated against a representative strain of HCoV (HCoV-229E) in MRC5 cells. These findings may help to explain the previously evidenced crossreactivity and neutralization activity for SARS-CoV-2 observed with pre-pandemic IG products (Díez et al., 2020a , Díez et al., 2020b , and differences in illness behavior among patients. Antibody levels (measured by IgG ELISA and expressed as Ig anti-HCoV units /mg IgG) to human common coronaviruses grouped by geographic origin of the plasma pool. Differences were seen among the common HCoV strains studied, but there were no statistically significant differences between product derived from plasma of different geographic origins (ANOVA p value 0.90).

HCoV-229E virus neutralization. Neutralization of HCoV-229E was measured in a cytopathic assay in MRC5 cells. Concentration-effect curves (mg IgG/mL-neutralization %) were generated for virus neutralization and IC50 values were calculated. The IC50 for Flebogamma ® -DIF was 0.503 mg IgG/mL which was very similar to the IC50 for Gamunex ® -C (0.553 mg IgG/mL).

All the relevant data that support the findings of this study are available within the article and its supplementary material. Complementary data can be available from the corresponding author upon reasonable request (josemaria.diez@grifols.com).

Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection

Global patterns in coronavirus diversity

Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests

Antigenic cross-reactivity between severe acute respiratory syndrome-associated coronavirus and human coronaviruses 229E and OC43

Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens

Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins

Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method

Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)

A new virus isolated from the human respiratory tract

Serologic crossreactivity of SARS-CoV-2 with endemic and seasonal betacoronaviruses

Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses

Distinct antibody repertoires against endemic human coronaviruses in children and adults

Human coronavirus circulation in the United States

High incidence but low burden of coronaviruses and preferential associations between respiratory viruses

Systematically mapping clinical features of infections with classical endemic human coronaviruses

Increased Detection of Viruses in Children with Respiratory Tract Infection Using PCR

Detection of the human coronavirus 229E, HKU1, NL63, and OC43 between 2010 and 2013 in

Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease

Does common cold coronavirus infection protect against severe SARS-CoV-2 disease?

An Outbreak of Human Coronavirus OC43 Infection and Serological Cross-reactivity with SARS Coronavirus

Identification of the receptor-binding domain of the spike glycoprotein of human betacoronavirus HKU1

Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products

Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients

Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses

Identification of a new human coronavirus

Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia

Etiology and clinical characteristics of SARS-CoV-2 and other human coronaviruses among children in Zhejiang Province